Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells

Molecular Medicine Reports

Volumn 14, Issue 3, 2016, Pages 1957-1962

  Zeng, Yan Ping ^a   Yang, Chao ^a   Li, Yuan ^a   Fan, Yong ^a   Yang, Hong Jun ^a   Liu, Bin ^a   Sang, Hong Xun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

MAPK; NF B; Osteoclast; Osteoporosis

Indexed keywords

ACETYLSALICYLIC ACID; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; CATHEPSIN K; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOFLUORESCENCE TEST; MARKER GENE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PROTEIN PHOSPHORYLATION; QUANTITATIVE STUDY; RAW 264.7 CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BONE DEVELOPMENT; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ASPIRIN; CATHEPSIN K; CELL DIFFERENTIATION; DOWN-REGULATION; MATRIX METALLOPROTEINASE 9; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; PHOSPHORYLATION; RANK LIGAND; RAW 264.7 CELLS; RECEPTORS, CALCITONIN; SIGNAL TRANSDUCTION;

EID: 84989205054     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5456     Document Type: Article

References (25)

1. Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003
2. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277: 44347-44356, 2002
3. Wei S, Teitelbaum SL, Wang MW and Ross FP: Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142: 1290-1295, 2001
4. Matsumoto M, Sudo T, Saito T, Osada H and Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275: 31155-31161, 2000
5. David JP, Sabapathy K, Hoffmann O, Idarraga MH and Wagner EF: JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci 115: 4317-4325, 2002
6. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH and Kim HH: The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved inosteoclast differentiation. Bone 30: 71-77, 2002
7. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, et al: Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758-763, 2004
8. Baltas CS, Balanika AP, Raptou PD, Tournis S and Lyritis GP; Hellenic guidelines on bone densitometry working group: Clinical practice guidelines proposed by the Hellenic Foundation of Osteoporosis for the management of osteoporosis based on DXA results. J Musculoskelet Neuronal Interact 5: 388-392, 2005
9. Valverde P: Pharmacotherapies to manage bone loss-associated diseases: A quest for the perfect benefit-to-risk ratio. Curr Med Chem 15: 284-304, 2008
10. Li L and Seeram NP: Further investigation into maple syrup yields 3 new lignans, a new phenylpropanoid, and 26 other phytochemicals. J Agric Food Chem 59: 7708-7716, 2011
11. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K and Nevitt MC: Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11: 29-35, 1996
12. Chen ZW, Wu ZX, Sang HX, Qin GL, Wang LS, Feng J, Wang J, Li XJ, Wang JC and Zhang D: Effect of aspirin administration for the treatment of osteoporosis in ovariectomized rat model. Zhonghua Yi Xue Za Zhi 91: 925-929, 2011 (In Chinese)
13. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001
14. Raisz LG: Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115: 3318-3325, 2005
15. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA and Wagner EF: c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448, 1994
16. Mansky KC, Sankar U, Han J and Ostrowski MC: Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem 277: 11077-11083, 2002
17. Gingery A, Bradley E, Shaw A and Oursler MJ: Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 89: 165-179, 2003
18. Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H and Miyahara T: Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 41: 592-602, 2007
19. Anusaksathien O, Laplace C, Li X, Ren Y, Peng L, Goldring SR and Galson DL: Tissue-specific and ubiquitous promoters direct the expression of alternatively spliced transcripts from the calcitonin receptor gene. J Biol Chem 276: 22663-22674, 2001
20. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ and Fisher DE: Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 98: 5798-5803, 2001
21. Reddy SV, Hundley JE, Windle JJ, Alcantara O, Linn R, Leach RJ, Boldt DH and Roodman GD: Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res 10: 601-606, 1995
22. Choi HJ, Park YR, Nepal M, Choi BY, Cho NP, Choi SH, Heo SR, Kim HS, Yang MS and Soh Y: Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Eur J Pharmacol 636: 28-35, 2010
23. Bharti AC, Takada Y and Aggarwal BB: Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172: 5940-5947, 2004
24. Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81-S96, 2002
25. Karin M, Yamamoto Y and Wang QM: The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 3: 17-26, 2004